Venture capital firm Frazier Healthcare Partners has spun out a US-based antibiotics developer with the help of grant funding from a Boston University-operated body and a $8.5m series A round.

Healthcare-focused venture capital firm Frazier Healthcare Partners has spun out US-based antibiotics developer Recida Therapeutics with a grant from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (Carb-X), an international research funding body operated by Boston University.
Carb-X’s award of up to $4.4m will complement capital from Recida’s $8.5m series A financing round, led by Frazier Healthcare Partners with backing from undisclosed additional investors.
Recida Therapeutics’ lead asset, RC-01, is designed to treat serious antibiotic-resistant infections where gram-negative bacteria resilient to…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?